I.K. Gujral Punjab Technical University, Kapurthala, Punjab, India.
Kota College of Pharmacy, Kota, Rajasthan, India.
Curr Pharm Des. 2018;24(22):2573-2582. doi: 10.2174/1381612824666180820150150.
Parkinson's disease (PD) is standout amongst the most common neurodegenerative malady with unpredictable dynamic pathology. At present, accessible traditional choices for PD have certain impediments of their own, and subsequently persistent consistence and fulfillment are low. Current contemporary treatment options just give symptomatic alleviation constrained control to anticipate malady progression, bringing about poor patient consistence and fulfilment. Numerous rising pharmacotherapies for PD are in various phases of medical improvement. Treatments incorporate adenosine A2A receptor antagonists, anti-apoptotic agents, monoamine oxidase inhibitors, glutamate receptor antagonists, and antioxidants for example, N-acetyl cysteine, edaravone, and coenzyme Q10. Other rising nonpharmacotherapies incorporate microRNAs, viral vector gene therapy, stem cells transglutaminases, RTP801, and glial derived neurotrophic factor (GDNF). Furthermore, surgeries including profound pallidotomy, deep brain stimulation, thalamotomy and gamma knife surgery have developed as elective mediations for cutting edge PD patients who have totally used common medications and still suffer from unrelenting motor symptoms. Complementary and Alternative medicine (CAM) modalities, such as Yoga, acupuncture, Tai Chi, Music therapies are highly practiced in several countries, offer some of the safer and effective treatment modalities for PD. While a few of these treatments hold much assurance in postponing the beginning of ailment and moderating its progression, more pharmacotherapies and careful mediations should be examined in various phases of PD. Therefore, the main objective of our review is to fill the gap between the researches and provide updated and productive information about the research reported in the last couple of years and can fulfil the most reassuring plausibility for encourage treatment of Parkinson Disease.
帕金森病(PD)是最常见的神经退行性疾病之一,具有不可预测的动态病理学。目前,可用的传统 PD 选择具有自身的某些障碍,因此持续一致性和满意度较低。目前的当代治疗选择仅提供症状缓解,对疾病进展的控制有限,导致患者一致性和满意度差。许多新兴的 PD 药物治疗方法处于不同的药物开发阶段。治疗方法包括腺苷 A2A 受体拮抗剂、抗细胞凋亡剂、单胺氧化酶抑制剂、谷氨酸受体拮抗剂和抗氧化剂,例如 N-乙酰半胱氨酸、依达拉奉和辅酶 Q10。其他新兴的非药物治疗方法包括 microRNAs、病毒载体基因治疗、神经胶质细胞转谷氨酰胺酶、RTP801 和胶质细胞源性神经营养因子(GDNF)。此外,深部苍白球切开术、深部脑刺激、丘脑切开术和伽马刀手术等手术已发展成为先进 PD 患者的选择性治疗方法,这些患者已经完全使用了常规药物,但仍遭受持续的运动症状困扰。补充和替代医学(CAM)模式,如瑜伽、针灸、太极、音乐疗法,在许多国家得到广泛应用,为 PD 提供了一些更安全有效的治疗方法。虽然其中一些治疗方法在延缓疾病发作和减缓其进展方面有很大的希望,但在 PD 的不同阶段,应该对更多的药物治疗和手术治疗进行研究。因此,我们的综述的主要目的是填补研究之间的空白,并提供关于过去几年报告的研究的最新和富有成效的信息,并为鼓励治疗帕金森病提供最可靠的可能性。